# Danco Laboratories

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/danco-laboratories
Canonical HTML page: https://getbiobrief.com/entity/danco-laboratories

## Timeline

- **2025**: Data Stabilization — National reports confirm abortion rates remain steady despite ongoing state restrictions.
- **2024-06**: SCOTUS Ruling — Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
- **2024-03**: Retail Launch — CVS and Walgreens begin dispensing abortion pills in select states.
- **2023-01**: FDA Rule Change — FDA officially allows retail pharmacies to dispense mifepristone with a prescription.
- **2022-06**: Dobbs Decision — U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans.
- **2022-06**: Dobbs Decision — SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.
- **2021-12**: Telehealth Shift — FDA permanently removes the requirement that mifepristone be dispensed in person.
- **2016-03**: Label Update — FDA expands usage to 70 days gestation and reduces required office visits.
- **2000-09**: FDA Approval — FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.

## Recent coverage (2 stories)

### Medication Abortion Dominates US Market Amid Escalating Regulatory Warfare
2026-03-24 07:47:20 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
Full story: https://getbiobrief.com/story/medication-abortion-market-trends-2026

### U.S. Abortion Rates Remain Resilient Amid State Bans and Telehealth Surge
2026-03-24 07:46:46 · Sentiment: Neutral · Impact: 7/10 · Sources: 10

National data reveals that abortion rates in the United States have remained steady or increased despite a wave of state-level bans following the Dobbs decision. This trend is driven by a significant shift toward medication abortion and the rapid expansion of telehealth services protected by state shield laws.
Full story: https://getbiobrief.com/story/us-abortion-rates-resilient-telehealth-pharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.